← Back to headlines
Eli Lilly's Retatrutide Shows Strong Phase 3 Trial Results
CNBC reports that Eli Lilly has announced robust Phase 3 trial results for its drug Retatrutide, indicating promising efficacy.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
